Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 340articles · 30d
- 1+ hour agolatest article
- Aug 17, 2026earliest in window
- 91%with images
- 291avg words
- Economy, Business & Finance 195
- Health & Wellness 159
- Medical 158
- Business & Industrial 142
- Finance & Business 132
- Health 75
- Science & Technology 53
- Science & Nature 34
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Three Life-Saving Medical Technologies Named Finalists for the Second Annual Thomas J. Fogarty Innovation Prize
2+ day, 23+ hour ago (335+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
NEURELIS CEO CRAIG CHAMBLISS TO PRESENT KEYNOTE AT THE 14TH ANNUAL OUTSOURCING IN CLINICAL TRIALS SOUTHERN CALIFORNIA 2026 CONFERENCE
2+ day, 23+ hour ago (319+ words) SAN DIEGO, Sept. 10, 2026 /PRNewswire/ -- Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced its Founder and Chief Executive Officer Craig Chambliss will give a keynote address at the 14th Annual Outsourcing Clinical Trials (OCT) Southern California 2026 conference, to be…...
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
2+ day, 23+ hour ago (346+ words) Despite advances in care, most patients with FL eventually experience relapse, highlighting the need for additional treatment options across multiple lines of therapy.3 The acceptance of cancer therapies such as MINJUVI® in the treatment of FL represents a significant step,…...
BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology
3+ day, 11+ hour ago (399+ words) PARIS--(BUSINESS WIRE)--BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. The…...
Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake"
3+ day, 12+ hour ago (406+ words) No more is launching a drug a “straight math exercise,” as Most Favored Nation drug pricing pressures drugmakers to reconsider launch sequences to ensure the best price can be achieved in the main global market: the United States. That’s according…...
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
3+ day, 17+ hour ago (205+ words) Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium…...
Massive Bio and PrecisCa Announce Strategic Partnership to Expand Cancer Patient Access to Clinical Trials Across the U.S.
4+ day, 6+ min ago (485+ words) BioSpace Massive Bio and PrecisCa Announce Strategic Partnership to Expand Cancer Patient Access to Clinical Trials Across the U.S. Collaboration combines Massive Bio's AI-driven trial matching and concierge support with PrecisCa's oncology provider network to increase patient surfacing and trial enrollment…...
LEO Pharma Inc. (Canada) Finalizes Letter of Intent with pCPA for Anzupgo® (delgocitinib cream) for Chronic Hand Eczema
4+ day, 12+ hour ago (296+ words) CHE can have a significant impact on quality of life, daily functioning, and employment.5 This burden is felt most acutely by healthcare professionals who spend their days washing their hands, wearing gloves, and working with irritants.6 “Chronic hand eczema can…...
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
4+ day, 11+ hour ago (169+ words) Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030 The Company expects XP-8121 peak net revenue potential of $1 to $3 billion Capstone — Pediatric Study Touchstone — Special Population Study Clinical Perspective…...
Lotus Neuro Launches to Deliver the Next Generation of Therapies Across the Blood-Brain Barrier
4+ day, 11+ hour ago (216+ words) Through its Proof of Pharmacology (POP) Challenge, launched in June 2026, Lotus Neuro is funding investigators at leading neuroscience institutions to add focused ultrasound study arms to existing investigational drug programs, generating clinical evidence of drug delivery and target engagement in…...